Search bioRxiv⌕ Search

Biology subjects

MANTIS, N. J.

Publications and source records attributed to MANTIS, N. J..

10 recordsLinked to original sources

Rapid motility arrest of the Lyme disease spirochete, Borrelia burgdorferi, by vaccine-induced OspA antibodies

Outer surface protein A (OspA)-based Lyme disease vaccines elicit antibodies that inhibit transmission of infectious Borrelia burgdorferi spirochetes from ticks to humans, although the mechanism by which this occurs is unclear. Here we demonstrate using high-resolution, single-cell fluorescence video microscopy that B. burgdorferi motility is arrested within minutes by human OspA-specific monoclonal antibodies and polyclonal OspA antisera from mice immunized with a candidate OspA mRNA lipid nanoparticle vaccine.

immunology↗

OspA Antibodies Inhibit the In vitro Transmigration of Borreliellia burgdorferi

Antibodies against Outer surface protein A (OspA) block tick-to-mammal transmission of the Lyme disease spirochete, Borreliella burgdorferi. Evidence suggests that antibodies ingested by a tick during a blood meal entrap OspA-expressing B. burgdorferi within the tick midgut and prevent spirochete migration to the salivary gland and host dermis. In this study, we employed a recently described Transwell system to quantitate the impact of OspA antibodies on B. burgdorferi transmigration. We demonstrate that spirochete movement from the lower Transwell chamber to the upper chamber over a 20-hour period was reduced by >99% in the presence of the transmission-blocking mouse monoclonal IgG antibody (mAb) LA-2. In the case of LA-2, transmigration inhibition coincided with the formation of large antibody-induced bacterial aggregates in the lower Transwell chamber, as determined by dark field microscopy and flow cytometry. Further examination of a panel of human OspA mAbs of varying affinities and epitope specificities revealed that virtually all could block B. burgdorferi transmigration, although most did so in the absence of measurable spirochete agglutination. We propose that transmigration arrest may represent a possible mechanism by which OspA antibodies entrap B. burgdorferi in the tick midgut and limit transmission to mammalian hosts.

immunology↗

Maternal transfer of mRNA LNP-derived, pathogen-specific, monoclonal IgG to suckling mice

Breast milk provides a rich source of naturally derived maternal antibodies that confer passive immunity to infants, protecting them from a variety of respiratory and enteric infections. For at-risk newborns in low- and middle-income countries, supplementing breast milk with pathogen-specific neutralizing and bactericidal antibodies could offer significant short- and long-term health benefits. In this study, we explored the use of mRNA and lipid nanoparticle (LNP) technology to deliver a Vibrio cholerae-specific monoclonal IgG antibody ("ZAC-3") into the milk of lactating mice. Swiss Webster mice were intravenously administered ZAC-3 IgG mRNA-LNPs, and we monitored serum and breast milk for the presence of V. cholerae-specific human IgG1. A single injection of mRNA-LNPs led to rapid and sustained expression of ZAC-3 IgG in both the blood and breast milk of lactating dams. ZAC-3 IgG1 in these samples recognized whole V. cholerae cells by ELISA and exhibited potent vibriocidal activity in the presence of human complement. Furthermore, ZAC-3 IgG was detected in the sera of suckling pups at levels proportional to those in the mothers, demonstrating successful transfer of functional antibodies to the newborns. In conclusion, our findings highlight the potential of mRNA-based monoclonal antibody platforms in the maternal-newborn context and address key challenges associated with the direct delivery of recombinant antibodies.

immunology↗

A type-specific B cell epitope at the apex of Outer surface protein C (OspC) of the Lyme disease spirochete, Borreliella burgdorferi

Broadly protective immunity to the Lyme disease spirochete, Borreliella burgdorferi, is constrained by an overwhelming antibody response against type-specific epitopes on Outer surface protein C (OspC), a homodimeric helix-rich lipoprotein essential for early stages of spirochete dissemination in vertebrate hosts. However, the molecular basis for type-specific immunity has not been fully elucidated. In this report, we produced and characterized an OspC mouse monoclonal antibody, 8C1, that recognizes native and recombinant OspC type A (OspCA) but not OspC types B or K, and arrests B. burgdorferi motility independent of complement. Epitope mapping by HDX-MS localized 8C1s epitope to a protruding ridge on the apex of OspCA -helix 3 (residues 130-150) previously known to be an immunodominant region of the molecule. Alanine scanning pinpointed 8C1s core binding motif to a solvent exposed patch consisting of residues K141 H142 T143 D144. In parallel, analysis of 26 Lyme disease positive serum samples confirmed antibody reactivity with this region of OspCA, with residues E140 and D144 as being most consequential. Our results underscore the importance of -helix 3 as a target of type-specific epitopes on OspCA across mice and humans that should be taken into consideration in Lyme disease vaccine design.

immunology↗

Antibody Profiles Elicited by Potent and Subpotent Whole Cell Pertussis Vaccines in Mice

Inactivated, whole cell pertussis (wP) vaccines remain at the frontline in the global fight against the resurgence of whooping cough, especially in low- and middle-income countries. However, the reliance on the intracerebral mouse potency test (ic-MPT or Kendrick assay) as the standard batch release assay is challenging for the production of commercial wP vaccines. The ic-MPT is technically challenging, labor intensive and, arguably, incongruous with modern animal welfare guidelines. Replacing the ic-MPT with a whole cell Bordetella pertussis ELISA, the so-called pertussis serology potency test (PSPT), has shown promise, but has been difficult to implement in practice. In this report, we tested the hypothesis that potent and subpotent wP vaccines have distinct serologic profiles in mice that could be developed as a substitute for the ic-MPT. We first established an accelerated decay (thermal stress) protocol in which wP, in the context of DTwP, was rendered >10-fold less effective than unstressed vaccine when evaluated in a mouse model of B. pertussis lung clearance following intranasal challenge. We then screened immune sera on a limited B. pertussis Tahoma I proteome array and identified >30 antigens whose antibody reactivity profiles increased, decreased or were unchanged as a function of wP potency. Interestingly, virtually all the "indicator" antigens identified are known virulence factors or reactive with human convalescent sera, thereby establishing a potential link between wP potency and pertussis infection and immunity. These results bode well for the development of a limited B. pertussis antigen array as a stability-indicating surrogate potency assay for the ic-MPT.

immunology↗

Inter-laboratory harmonization of microsphere immunoassays for SARS-CoV-2 antibody detection in dried blood spots and oral fluids

Dried blood spots (DBS) and oral fluids (OF) are easily attainable biospecimen types that have enabled population scale antibody monitoring for SARS-CoV-2 exposure and vaccination. However, the degree to which the two different biospecimen types can be used interchangeably remains unclear. To begin to address this question, we generated contrived DBS (cDBS) and OF (cOF) from serum panels from SARS-CoV-2 infected, vaccinated, and uninfected individuals. The contrived samples were evaluated using SARS-CoV-2 multiplexed microsphere immunoassays (MIAs) at two different institutions. Intra-laboratory tests revealed near perfect agreement between cDBS and cOF for N and S antigens, as evidenced by {kappa} = 0.97-1 and 98%-100% agreement. Inter-laboratory comparisons were equally robust for both N ({kappa} = 0.94-0.96; 97.5%-98 % agreement) and S ({kappa} = 0.98 -1.0; 99.0%-100%). Furthermore, assays were transferred between labs, including methods and reagents, and a subset of cDBS and cOF samples (n = 52) were tested. Qualitative concordance remained high ({kappa} = 0.94-1.0; 97.5%-100% agreement), confirming that integrity of the assays is retained upon transfer. In summary, our results provide evidence that DBS and OF can be used interchangeably across laboratories and institutions for the qualitative assessment of SARS-CoV-2 antibody determinations.

immunology↗

Quantitating SARS-CoV-2 Neutralizing Antibodies from Human Dried Blood Spots

BackgroundIn the earliest days of COVID-19 pandemic, the collection of dried blood spots (DBS) enabled public health laboratories to undertake population-scale seroprevalence studies to estimate rates of SARS-CoV-2 exposure. With SARS-CoV-2 seropositivity levels now estimated to exceed 94% in the United States, attention has turned to using DBS to assess functional (neutralizing) antibodies within cohorts of interest. MethodsContrived DBS eluates from convalescent, fully vaccinated and pre-COVID-19 serum samples were evaluated in SARS-CoV-2 plaque reduction neutralization titer (PRNT) assays, a SARS-CoV-2 specific 8-plex microsphere immunoassay, a cell-based pseudovirus assay, and two different spike-ACE2 inhibition assays, an in-house Luminex-based RBD-ACE2 inhibition assay and a commercial real-time PCR-based inhibition assay (NAB-Sure). ResultsDBS eluates from convalescent individuals were compatible with the spike-ACE2 inhibition assays, but not cell-based pseudovirus assays or PRNT. However, the insensitivity of cell-based pseudovirus assays was overcome with DBS eluates from vaccinated individuals with high SARS-CoV-2 antibody titers. ConclusionSARS-CoV-2 neutralizing titers can be derived with confidence from DBS eluates, thereby opening the door to the use of these biospecimens for the analysis of vulnerable populations and normally hard to reach communities.

immunology↗

Inflammatory Profiles Induced following Intranasal Vaccination with Ricin Toxin-Immune Complexes

Ricin toxin (RT), a ribosome-inactivating protein derived from castor beans (Ricinus communis), is lethal in extremely small doses via inhalation, due in part to pulmonary inflammation triggeredby the toxin. While no licensed countermeasures for RT exists, a myriad of toxin-neutralizing monoclonal antibodies (mAbs) against RTs enzymatic (RTA) and binding (RTB) subunits have been described, including PB10 (anti-RTA) and SylH3 (anti-RTB). We recently demonstrated that a single administration of PB10 and SylH3 as an RT immune complex (RIC) to mice by the intranasal route functions as a potent immunogen, stimulating the rapid onset of high titer toxin-neutralizing antibodies that persist for months. In this report, we demonstrate that the de novo antibody response following RICs exposure is wholly dependent on CD4+ T cell help, as treatment of mice with an anti-CD4 monoclonal antibody abrogated the onset of RT-specific antibodies. To investigate other immunological factors associated with RICs, we examined the early local and systemic inflammatory cytokine and chemokine responses associated with intranasal RT and RIC administration. We report that RICs stimulate an inflammatory profile in the bronchoalveolar lavage fluids (BALF) and serum similar to that elicited by RT itself, but markedly reduced in magnitude. Of the 32 analytes examined, the most pronounced were IL-6, KC (CXCL1), G-CSF, and GM-CSF. To evaluate the role of IL-6 in driving the de novo onset of RT antibodies, groups of mice were treated (or not) with an IL-6 neutralizing monoclonal antibody prior to intranasal RICs challenge. While the monoclonal antibody treatment successfully depleted circulating IL-6 to levels below detection, it had no impact on the kinetics or magnitude of RICs-induced RT-specific antibody response. Thus, our results suggest that other cytokines/chemokines triggered by RICs are involved in influencing long lasting durable antibody responses to RT.

immunology↗

Endpoint and Epitope-specific Antibody Responses as Correlates of Vaccine-mediated Protection of Mice against Ricin Toxin

The successful licensure of vaccines for biodefense is contingent upon the availability of well-established correlates of protection (CoP) in at least two animal species that can then be applied to humans, without the need to assess efficacy in the clinic. In this report we describe a multivariate model that combines pre-challenge serum antibody endpoint titers (EPT) and values derived from an epitope profiling immune-competition capture (EPICC) assay as a predictor in mice of vaccine-mediated immunity against ricin toxin (RT), a Category B biothreat. EPICC is a modified competition ELISA in which serum samples from vaccinated mice were assessed for their ability to inhibit the capture of soluble, biotinylated (b)-RT by a panel of immobilized monoclonal antibodies (mAbs) directed against four immunodominant toxin-neutralizing regions on the enzymatic A chain (RTA) of RT. In a test cohort of mice (n=40) vaccinated with suboptimal doses of the RTA subunit vaccine, RiVax(R), we identified two mAbs, PB10 and SyH7, which had EPICC inhibition values in pre-challenge serum samples that correlated with survival following a challenge with 10 x LD50 of RT administered by intraperitoneal (IP) injection. Analysis of a larger cohort of mice (n=645) revealed that a multivariate model combining endpoint titers and an epitope-profiling immune-competition capture (EPICC) assay values for PB10 and SyH7 as predictive variables had significantly higher statistical power than any one of the independent variables alone. Establishing the correlates of vaccine-mediated protection in mice represents an important steppingstone in the development of RiVax(R) as a medical countermeasure under the United States Food and Drug Administrations "Two Animal Rule."

immunology↗

Intracellular Neutralization of Ricin Toxin by Single Domain Antibodies Targeting the Active Site Pocket

The extreme potency of the plant toxin, ricin, is due to its enzymatic subunit, RTA, which inactivates mammalian ribosomes with near perfect efficiency. Here we characterized, at the functional and structural levels, seven alpaca single-domain antibodies (VHHs) previously reported to recognize epitopes in proximity to RTAs active site. Three of the VHHs, V2A11, V8E6 and V2G10, were potent inhibitors of RTA in vitro and protected Vero cells from ricin when expressed as intracellular antibodies (\"intrabodies\"). Crystal structure analysis revealed that the complementarity-determining region 3 (CDR3) elements of V2A11 and V8E6 penetrate RTAs active site and interact with key catalytic residues. V2G10, in contrast, sits atop the enzymatic pocket and occludes substrate accessibility. The other four VHHs also penetrated/occluded RTAs active site, but lacked sufficient binding affinities to outcompete RTA-ribosome interactions. Intracellular delivery of high-affinity, single-domain antibodies may offer a new avenue in the development of countermeasures against ricin toxin.

immunology↗